TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 ASIA-PACIFIC 99
15.1.1 JAPAN 106
15.1.2 CHINA 108
15.1.3 INDIA 110
15.1.4 SOUTH KOREA 112
15.1.5 AUSTRALIA 114
15.1.6 SINGAPORE 116
15.1.7 THAILAND 118
15.1.8 MALAYSIA 120
15.1.9 INDONESIA 122
15.1.10 PHILIPPINES 124
15.1.11 VIETNAM 126
15.1.12 TAIWAN 128
15.1.13 REST OF ASIA-PACIFIC 130
16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 131
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 131
17 SWOT ANALYSIS 132
18 COMPANY PROFILE 133
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 133
18.1.1 COMPANY SNAPSHOT 133
18.1.2 REVENUE ANALYSIS 133
18.1.3 COMPANY SHARE ANALYSIS 134
18.1.4 PRODUCT PORTFOLIO 134
18.1.5 RECENT DEVELOPMENTS 134
18.2 GENENTECH, INC. 135
18.2.1 COMPANY SNAPSHOT 135
18.2.2 COMPANY SHARE ANALYSIS 135
18.2.3 PRODUCT PORTFOLIO 136
18.2.4 RECENT DEVELOPMENTS 136
18.3 SANDOZ INTERNATIONAL GMBH 137
18.3.1 COMPANY SNAPSHOT 137
18.3.2 COMPANY SHARE ANALYSIS 137
18.3.3 PRODUCT PORTFOLIO 138
18.3.4 RECENT DEVELOPMENTS 138
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 139
18.4.1 COMPANY SNAPSHOT 139
18.4.2 REVENUE ANALYSIS 139
18.4.3 COMPANY SHARE ANALYSIS 140
18.4.4 PRODUCT PORTFOLIO 140
18.4.5 RECENT DEVELOPMENTS 140
18.5 ACCORD HEALTHCARE U.S. 141
18.5.1 COMPANY SNAPSHOT 141
18.5.2 COMPANY SHARE ANALYSIS 141
18.5.3 PRODUCT PORTFOLIO 142
18.5.4 RECENT DEVELOPMENTS 142
18.6 ABBVIE INC. 143
18.6.1 COMPANY SNAPSHOT 143
18.6.2 REVENUE ANALYSIS 143
18.6.3 PRODUCT PORTFOLIO 144
18.6.4 RECENT DEVELOPMENTS 144
18.7 ALPINE IMMUNE SCIENCES 145
18.7.1 COMPANY SNAPSHOT 145
18.7.2 REVENUE ANALYSIS 145
18.7.3 PRODUCT PORTFOLIO 146
18.7.4 RECENT DEVELOPMENTS 146
18.8 BELLBROOK LABS 147
18.8.1 COMPANY SNAPSHOT 147
18.8.2 PRODUCT PORTFOLIO 147
18.8.3 RECENT DEVELOPMENTS 147
18.9 BIOMX 148
18.9.1 COMPANY SNAPSHOT 148
18.9.2 REVENUE ANALYSIS 148
18.9.3 PRODUCT PORTFOLIO 149
18.9.4 RECENT DEVELOPMENTS 149
18.10 BRISTOL-MYERS SQUIBB COMPANY 150
18.10.1 COMPANY SNAPSHOT 150
18.10.2 REVENUE ANALYSIS 150
18.10.3 PRODUCT PORTFOLIO 151
18.10.4 RECENT DEVELOPMENTS 151
18.11 CAMBER PHARMACEUTICALS, INC. 152
18.11.1 COMPANY SNAPSHOT 152
18.11.2 PRODUCT PORTFOLIO 152
18.11.3 RECENT DEVELOPMENTS 152
18.12 ENVEDA 153
18.12.1 COMPANY SNAPSHOT 153
18.12.2 PRODUCT PORTFOLIO 153
18.12.3 RECENT DEVELOPMENTS 153
18.13 GILEAD SCIENCES, INC. 154
18.13.1 COMPANY SNAPSHOT 154
18.13.2 REVENUE ANALYSIS 154
18.13.3 PRODUCT PORTFOLIO 155
18.13.4 RECENT DEVELOPMENTS 155
18.14 INTERCEPT PHARMACEUTICALS, INC. 156
18.14.1 COMPANY SNAPSHOT 156
18.14.2 REVENUE ANALYSIS 156
18.14.3 PRODUCT PORTFOLIO 157
18.14.4 RECENT DEVELOPMENTS 157
18.15 KITHER BIOTECH S.R.L. 158
18.15.1 COMPANY SNAPSHOT 158
18.15.2 PRODUCT PORTFOLIO 158
18.15.3 RECENT DEVELOPMENTS 158
18.16 PHARMAXIS LTD 159
18.16.1 COMPANY SNAPSHOT 159
18.16.2 REVENUE ANALYSIS 159
18.16.3 PRODUCT PORTFOLIO 160
18.16.4 RECENT DEVELOPMENTS 160
18.17 REDX PHARMA PLC. 161
18.17.1 COMPANY SNAPSHOT 161
18.17.2 REVENUE ANALYSIS 161
18.17.3 PRODUCT PORTFOLIO 162
18.17.4 RECENT DEVELOPMENTS 162
18.18 VERONA PHARMA PLC 163
18.18.1 COMPANY SNAPSHOT 163
18.18.2 REVENUE ANALYSIS 163
18.18.3 PRODUCT PORTFOLIO 164
18.18.4 RECENT DEVELOPMENTS 164
19 QUESTIONNAIRE 165
20 RELATED REPORTS 168

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.